Full Press Release Details
Mr. Chung joined Senti Bio in 2022 and brings 15 years of investing, operations, board and advisory experience from a broad set of industries including life sciences, healthcare, technology, and consumer/retail. As an investor, he was responsible for the identification, evaluation, structuring, execution, and management of control-oriented equity and debt investments, working hand-in-hand with management teams and through board roles to drive value creation.
Mr. Chung began his career at UBS Investment Bank, in the Financial Sponsors, Leveraged Finance & Restructuring Group, where he worked on debt-financed transactions and restructuring advisory services related to over $25 billion of securities. Subsequently, he focused on investing roles at Health Evolution Partners, a $500 million operations-oriented private equity fund focused on high-growth healthcare businesses, and the mezzanine group at Crescent Capital Group, a $3 billion fund focused on high-yield debt and equity investments. Across his investment experience, Mr. Chung was responsible for managing over a dozen portfolio companies, including the sale of 5, altogether worth nearly $1 billion of invested capital.
Mr. Chung earned his BS in Biomedical Computations and BA in Economics, both from Stanford University.